South San Francisco, CA June 20, 2017 Submitted by the Big Lift via FB On Friday, we received this message and photos from Andrea Jones, The Big Lift Initiative Officer at Silicon Valley Community Foundation, who has extensive…
Tag: Genentech
Genentech’s Alecensa (Alectinib) Phase III Results
South San Francisco, CA June 5, 2017 Genentech Press Release Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type…
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
South San Francisco, CA May 25, 2017 Genentech Press Release Actemra® is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra in GCA Sixth FDA…
Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
South San Francisco, CA May 10, 2017 Genentech Press Release 20 Genentech medicines are included in more than 190 abstracts during ASCO 2017 New pivotal results for Perjeta® (pertuzumab) and Alecensa® (alectinib) demonstrating improvement over standards of care Early…
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
South San Francisco, CA May 10, 2017 Genentech Press Release — IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy — –The safety profile was consistent with what has been previously observed for TECENTRIQ–…
Genentech’s Helix Cup Finals for SSFUSD Middle Schoolers Excites Future Scientists
South San Francisco, CA May 4, 2017 by Mel Ellison With cheers, more reminiscent of a sporting event then a science competition, teams from three South San Francisco Unified School District middle schools participated in the finals for the…
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
South San Francisco, CA April 17, 2017 Press Release Genentech First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy — SOUTH SAN FRANCISCO, CA —…
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
South San Francisco, CA March 29, 2017 Genentech Press Release First and only approved disease-modifying therapy for primary progressive form of multiple sclerosis (PPMS) – one of the most disabling forms of multiple sclerosis (MS) An…
Wish List Fulfilled for Ms. Lents’ Class at Parkway Heights Middle School
South San Francisco, CA January 3, 2017 Today Everything South City received a wonderful follow up notice from Ms Lents, one of our teachers at Parkway Heights Middle School. At the beginning of the school year, Ms. Lents along…
SSFUSD Teachers List of Supplies Needed: Genentech to match funds on projects
South San Francisco, Ca September 21, 2016 Gone are the old days when the schools would supply needed items for their students, as many parents can attest to the extensive list of things their kids must bring to school.…